Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $0.81 million during the quarter.
Northwest Biotherapeutics Trading Up 1.1%
Shares of NWBO stock opened at $0.19 on Friday. Northwest Biotherapeutics has a twelve month low of $0.14 and a twelve month high of $0.37. The stock has a fifty day simple moving average of $0.18 and a two-hundred day simple moving average of $0.21. The stock has a market capitalization of $324.11 million, a price-to-earnings ratio of -0.01 and a beta of -0.60.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Read More
- Five stocks we like better than Northwest Biotherapeutics
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
